Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Symphogen A/S. (5/29/14). "Press Release: Symphogen to Report Preliminary Safety and Exploratory Efficacy Data from a Phase 1 Study of Sym004, Anti-EGFR Monoclonal Antibody Mixture at ASCO". Copenhagen.

Organisations Organisation Symphogen A/S
  Group Symphogen (Group)
  Organisation 2 Merck KGaA
  Group Merck (DE) (Group)
Products Product Sym004 (anti-cancer pAb)
  Product 2 clinical research
Index term Index term Merck (DE)–Symphogen: antibody cancer drug, 201209–201501 ww license to Sym004 RIGHTS RETURNED 1/15
Persons Person Horak, Ivan (Symphogen 201405 CSO + CMO)
  Person 2 Drejer, Kirsten (Symphogen 2000–201608 Founding CEO since 201609 Executive Director)
     


Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today reported preliminary safety and exploratory efficacy data from a Phase 1 clinical study of Sym004, an investigational anti-EGFR monoclonal antibody mixture, administered biweekly, that will be presented in a poster at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting being held May 30 - June 3, 2014 in Chicago, IL. The poster, entitled, Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (29 pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment (abstract #3551) will be on view in the poster session on Gastrointestinal (Colorectal) Cancer (31 May 2014, 8:00 - 11:45 AM, McCormick Place Convention Center in Chicago, IL). Sym004 is a drug mixture of two mAbs targeting non-overlapping epitopes of EGFR which have been shown in pre-clinical studies to demonstrate synergistic inhibition of EGFR.

Chief Scientific and Medical Officer of Symphogen, Ivan Horak, MD, FACP, commented: "I am very pleased to see that the safety profile of this bi-weekly regimen is consistent with previous findings observed with the weekly schedule and the clinical activity of Sym004 in this very difficult to treat patient population with metastatic colorectal cancer, who are resistant to approved anti-EGFR antibodies. This administration schedule offers the potential to combine Sym004 with biweekly chemotherapy regimens used in first and second line therapy of metastatic CRC."

The ASCO data reports on 29 patients, whose median age was 64 years. Of the 29 patients, 86% had received more than two prior lines of therapy. One cohort of 12 patients was treated at 12 mg/kg and an additional 17 patients were treated at 18 mg/kg of Sym004 Q2W.

Safety Findings

No new or unexpected toxicities were identified. Drug-related adverse effects were manageable with dose reduction and supportive medication. In the 12 and 18 mg/kg cohorts, grade 3 skin rash was seen in 4/12 [33%] and 7/17 [41%] patients, respectively (no grade 4), and grade = 3 hypomagnesaemia was seen in 3/12 [25%] and 6/17 [35%] patients, respectively. Grade 3 diarrhea was seen in one patient of each cohort (8%; 6%; no grade 4). Infusion-related reactions were observed in 2/29 (7%) patients (grade 1 and 2, each).

Efficacy Findings

Antitumor activity, measured as disease control (stable disease [SD] + partial response [PR]), was documented in 14/29 (48%) patients.


About SYM004

Sym004 is comprised of two antibodies that are not only designed to block ligand binding, block receptor activation and downstream signaling but are also removal of the EGFR receptors from the cancer cell surface by inducing EGFR internalization and degradation.

Sym004 was out-licensed to Merck KGaA in 2012 following phase 2 clinical data in late stage cancer patients.


About Symphogen A/S

Symphogen is developing next-generation antibody therapeutics for the treatment of cancer and is dedicated to bringing truly innovative oncology products to the market.

The Company has advanced the frontier of antibody discovery by creating well-characterized antibody mixtures that address multiple oncology targets in a single drug product. The Company has matured its oncology pipeline and has currently brought two product candidates into the clinic. The Company's productive technology suite - capable of identifying, selecting and manufacturing optimal antibody mixtures - fuels Symphogen's innovative pipeline.

The lead oncology product Sym004 was out-licensed to Merck KGaA in 2012 following phase 2 clinical data in late stage cancer patients.

In total, the Company has raised €249 million in equity capital from premier international investors including Novo, Essex Woodlands Health Ventures and PKA, and employs 100 people, most of whom are based at Symphogen's facilities in Copenhagen.

Contacts

Symphogen A/S
Ivan Horak, MD FACP, +1 908-938-9313 (US cell) or +45 20 55 26 04 (DK cell)
Chief Scientific & Medical Officer
idh@symphogen.com
Kirsten Drejer, PhD, + 45 22 10 99 59
Chief Executive Officer
kd@symphogen.com
or
Annes Associates
Shari Annes, +1 650-888-0902
sannes@annesassociates.com

   
Record changed: 2017-04-02

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Symphogen (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top